Article
Hematology
Mahmoud R. Gaballa, Pinaki Banerjee, Denai R. Milton, Xianli Jiang, Christina Ganesh, Sajad Khazal, Vandana Nandivada, Sanjida Islam, Mecit Kaplan, May Daher, Rafet Basar, Amin Alousi, Rohtesh Mehta, Gheath Alatrash, Issa Khouri, Betul Oran, David Marin, Uday Popat, Amanda Olson, Priti Tewari, Nitin Jain, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Ken Chen, Richard Champlin, Elizabeth Shpall, Katayoun Rezvani, Partow Kebriaei
Summary: This study examined the feasibility and efficacy of blinatumomab in high-risk acute lymphoblastic leukemia patients after allogeneic hematopoietic cell transplantation. The results showed that blinatumomab treatment was feasible and effective in reducing the risk of relapse, with specific T-cell profiles associated with treatment response.
Review
Immunology
Mohammad Hassan Hodroj, Iman Abou Dalle, Nour Moukalled, Jean El Cheikh, Mohamad Mohty, Ali Bazarbachi
Summary: The outcome of B-cell acute lymphoblastic leukemia has improved with multi-agent chemotherapy and immunotherapeutic agents. However, relapse post-transplant is still common. This review discusses strategies such as tyrosine kinase inhibitors, innovative agents, and cellular therapy to prevent and overcome relapse post allo-HCT in ALL patients.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Cristina Tecchio, Anna Russignan, Mauro Krampera
Summary: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) benefits adult ALL patients, but those with MRD may require interventions with side effects. The significance of MFC in ALL treatment is widely recognized, but there is limited data on MRD monitoring in allo-HSCT settings. This article aims to summarize and discuss the role of MFC detection of MRD in adult ALL patients undergoing allo-HSCT, including sensitivity, timing, and relation to other MRD assessment techniques.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Yiwen Ling, Na Xu, Ke Zhao, Lijie Han, Qing Zhang, Zhiping Fan, Fen Huang, Zhuowen Chen, Li Xuan, Hui Liu, Jun Xu, Xiaoxia Chen, Sijian Yu, Hongsheng Zhou, Jing Sun, Qifa Liu
Summary: Emerging evidence suggests that CDKN2 deletion may be a poor prognostic predictor in adult B-ALL. Adult B-ALL patients with CDKN2 deletion may benefit from allogeneic hematopoietic cell transplant.
Article
Hematology
Alex F. Herrera, Kwang Woo Ahn, Carlos Litovich, Yue Chen, Amer Assal, Qaiser Bashir, Ruthee-Lu Bayer, Melanie Coleman, Zachariah DeFilipp, Nosha Farhadfar, Matthew Greenwood, Theresa Hahn, Mitchell Horwitz, Caron Jacobson, Samantha Jaglowski, Sylvie Lachance, Amelia Langston, Bassam Mattar, Richard T. Maziarz, Joseph McGuirk, Mohammad A. H. Mian, Sunita Nathan, Adrienne Phillips, Kevin Rakszawski, Henrik Sengeloev, Shalini Shenoy, Robert Stuart, Craig S. Sauter, Mohamed A. Kharfan-Dabaja, Mehdi Hamadani
Summary: Hematopoietic cell transplantation (HCT), including autologous and allogeneic HCT, may lead to durable remissions in therapy-sensitive patients with Richter syndrome. Complete response was associated with better outcomes in the allo-HCT cohort, while cytogenetic abnormalities and prior novel therapy did not impact outcomes.
Review
Oncology
Shukaib Arslan, Vinod Pullarkat, Ibrahim Aldoss
Summary: The treatment paradigm for ALL in adults, particularly the role of alloHCT, needs to be reevaluated with individualized decision-making. Advances in treatment options require consideration of various factors for complex decision-making.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2021)
Article
Oncology
Jia Liu, Zhong-Xing Jiang, Xin-Sheng Xie, Ding-Ming Wan, Wei-Jie Cao, Meng Wang, Zhen-Zhen Liu, Zhen-Kun Dong, Hai-Qiong Wang, Run-Qing Lu, Yin-Yin Zhang, Qian-Qian Cheng, Ji-Xin Fan, Wei Li, Fei He, Rong Guo
Summary: The study suggests that maintenance treatment with low-dose decitabine may help reduce relapse in adult ALL patients after allo-HSCT, especially in T-ALL patients. The occurrence of GVHD is relatively low during treatment, indicating good safety profile.
FRONTIERS IN ONCOLOGY
(2021)
Article
Hematology
Masamitsu Yanada, Takaaki Konuma, Satoshi Yamasaki, Shohei Mizuno, Shigeki Hirabayashi, Satoshi Nishiwaki, Naoyuki Uchida, Noriko Doki, Masatsugu Tanaka, Yukiyasu Ozawa, Masashi Sawa, Tetsuya Eto, Toshiro Kawakita, Shuichi Ota, Takahiro Fukuda, Makoto Onizuka, Takafumi Kimura, Yoshiko Atsuta, Shinichi Kako, Shingo Yano
Summary: This study aimed to compare the effect of disease status at the time of allogeneic hematopoietic cell transplantation (HCT) on post-transplant outcomes between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The study found significant differences in the effect of disease status on post-transplant outcomes between AML and ALL patients. Risk of relapse and overall mortality increased in a stepwise manner for both diseases when transplanted in CR3+ or non-CR, with stronger relevance in ALL patients. Further investigation with measurable residual disease data is suggested for future studies.
ANNALS OF HEMATOLOGY
(2021)
Article
Hematology
Riccardo Masetti, Edoardo Muratore, Davide Gori, Arcangelo Prete, Franco Locatelli
Summary: The selection of allo-HSCT for pediatric patients with AML in CR1 is still debated. This meta-analysis found that allo-HSCT improved overall survival and disease-free survival compared to chemotherapy in high-risk pediatric AML patients in CR1, but with an increased relapse rate. Sensitivity analysis confirmed the benefit of allo-HSCT on overall survival. Further research should focus on individualizing allo-HSCT indications based on molecular stratification and MRD monitoring.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Kinga Kwiecinska, Wojciech Strojny, Miroslaw Bik-Multanowski, Michal Korostynski, Marcin Piechota, Walentyna Balwierz, Szymon Skoczen
Summary: This study investigated the gene expression in children with high risk or relapsed ALL referred for HSCT. The results showed deep immunosuppression in these patients, which may enhance the probability of successful transplantation.
Article
Oncology
Ali Bazarbachi, Myriam Labopin, Mahmoud Aljurf, Riitta Niittyvuopio, Marie Balsat, Didier Blaise, Ibrahim Yakoub-Agha, Anna Grassi, Hans Christian Reinhardt, Stig Lenhoff, Pavel Jindra, Jakob Passweg, Iman Abou Dalle, Michael Stadler, Bruno Lioure, Patrice Ceballos, Eolia Brissot, Sebastian Giebel, Arnon Nagler, Christoph Schmid, Mohamad Mohty
Summary: The study found that there was a significant improvement in overall survival from posttransplant relapse for patients with Ph+ ALL over time, likely due to various factors including transplant-related factors, posttransplant salvage, and improvement in supportive care.
CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Satoshi Kaito, Shuhei Kurosawa, Yuho Najima, Emiko Sakaida, Naoki Shingai, Takahiro Fukuda, Takayoshi Tachibana, Naoyuki Uchida, Yukiyasu Ozawa, Masashi Sawa, Hideyuki Nakazawa, Shuichi Ota, Jun Kato, Hirohisa Nakamae, Yuta Katayama, Tetsuya Eto, Junji Tanaka, Yoshinobu Kanda, Yoshiko Atsuta, Yasuyuki Arai, Shinichi Kako
Summary: In the era of high-intensity chemotherapy, the outcomes of allo-HSCT for adult Ph-negative B-ALL patients in CR2 are inferior to those in CR1, mainly due to a higher relapse rate. Among CR2 patients, a short time between diagnosis and allo-HSCT is a significant risk factor for disease recurrence and overall mortality.
TRANSPLANTATION AND CELLULAR THERAPY
(2022)
Article
Biophysics
Han-zhou Qi, Jun Xu, Qian-qian Yang, Ren Lin, Zhi-xiang Wang, Ke Zhao, Qiang Wang, Xuan Zhou, Zhi-ping Fan, Fen Huang, Na Xu, Li Xuan, Hua Jin, Jing Sun, Robert Peter Gale, Hong-sheng Zhou, Qi-fa Liu
Summary: This study compared the transplant outcomes of adult T-cell acute lymphoblastic leukemia patients receiving pediatric-type or adult-type chemotherapy regimens pre-transplantation. The results showed that pediatric-type regimen was associated with lower relapse rates and better leukemia-free and overall survivals.
BONE MARROW TRANSPLANTATION
(2022)
Article
Immunology
Yan-Li Zhao, De-Yan Liu, Rui-Juan Sun, Jian-Ping Zhang, Jia-Rui Zhou, Zhi-Jie Wei, Min Xiong, Xing-Yu Cao, Yue Lu, Jun-fang Yang, Xian Zhang, Dao-Pei Lu, Peihua Lu
Summary: In B-ALL patients, similar clinical safety outcomes could be achieved with either CD19 CAR T-cell therapy followed by allo-HSCT or chemotherapy followed by allo-HSCT. Despite the inclusion of more patients with advanced diseases in the CAR-T group, the 4-year LFS and OS achieved with CAR T-cells followed by allo-HSCT were as remarkable as those achieved with chemotherapy followed by allo-HSCT.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Cell Biology
Mayumi Sugita, Takahiro Yamazaki, Mohammad Alhomoud, Jeremie Martinet, Jean-Baptiste Latouche, Encouse Golden, Olivier Boyer, Koen Van Besien, Silvia C. Formenti, Lorenzo Galluzzi, Monica L. Guzman
Summary: Autologous T cells engineered with CAR specific for CD19 have been approved for treating CD19(+) hematological malignancies. However, relapse often occurs when neoplastic cells lose CD19 expression. Preclinical models have shown that radiation therapy (RT) can overcome CD19 loss by inducing death receptor expression in cancer cells. Using a human model of CD19(+) acute lymphoblastic leukemia (ALL), it was found that low-dose total body irradiation (LD-TBI) administered before CAR T cell infusion significantly improved overall survival and CAR T cell expansion. These findings support the initiation of clinical trials combining LD-TBI with CAR T cells.
CELL DEATH & DISEASE
(2023)
Article
Oncology
Maria Victoria Mateos, Felipe Prosper, Jesus Martin Sanchez, Enrique M. Ocio, Albert Oriol, Cristina Motllo, Jean-Marie Michot, Isidro Jarque, Rebeca Iglesias, Maria Sole, Sara Martinez, Carmen Kahatt, Salvador Fudio, Gema Corral, Ali Zeaiter, Lola Montilla, Vincent Ribrag
Summary: The triple combination of plitidepsin, BTZ, and DXM showed moderate activity and acceptable safety in adult patients with relapsed/refractory multiple myeloma.
Article
Oncology
Meletios A. Dimopoulos, Albert Oriol, Hareth Nahi, Jesus San-Miguel, Nizar J. Bahlis, Saad Z. Usmani, Neil Rabin, Robert Z. Orlowski, Kenshi Suzuki, Torben Plesner, Sung-Soo Yoon, Dina Ben Yehuda, Paul G. Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Philippe Moreau
Summary: Based on the analysis of POLLUX, daratumumab in combination with lenalidomide and dexamethasone significantly prolonged progression-free survival in patients with relapsed or refractory multiple myeloma. The final analysis also showed that this combination therapy improved overall survival in these patients.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Letter
Oncology
Hareth Nahi, Saad Z. Usmani, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Albert Oriol, Torben Plesner, Nibedita Bandyopadhyay, Peter Hellemans, Brenda Tromp, Ivo Nnane, Donna Zemlickis, Ajai Chari, Philippe Moreau
LEUKEMIA & LYMPHOMA
(2023)
Editorial Material
Hematology
Robert K. Hills
Summary: Prolonged cytopaenia is a recognized issue after CAR-T cell therapy, but the causes and implications are still unknown. Kitamura et al.'s study identified that alterations in the bone marrow niche prior to CAR-T therapy may be a potential predictor for long-term cytopaenia, shedding light on this serious side-effect of treatment.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Alejandra Mendez Romero, Bronno van der Holt, Francois E. J. A. Willemssen, Rob A. de Man, Ben J. M. Heijmen, Steven Habraken, Henrike Westerveld, Otto M. van Delden, Heinz-Josef Klumpen, Eric T. T. L. Tjwa, Petra M. Braam, Sjoerd F. M. Jenniskens, Thomas Vanwolleghem, Reinhilde Weytjens, Olivier d'Archambeau, Judith de Vos-Geelen, Jeroen Buijsen, Christiaan van der Leij, Wilhelm den Toom, Dave Sprengers, Jan N. M. Ijzermans, Adriaan Moelker
Summary: In this multicenter randomized trial, the efficacy of transarterial chemoembolization delivered with drug eluting beads (TACE-DEB) was compared with stereotactic body radiation therapy (SBRT) in patients with hepatocellular carcinoma (HCC). The study found that SBRT showed higher local antitumoral activity than TACE-DEB, without detrimental effects on overall survival (OS), toxicity, and quality of life (QoL).
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Letter
Oncology
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel, Cyrille Touzeau, Sikander Ailawadhi, Britta Besemer, Javier de la Rubia Comos, Cristina Encinas, Maria-Victoria Mateos, Hans Salwender, Paula Rodriguez-Otero, Cyrille Hulin, Lionel Karlin, Anna Sureda Balari, Joan Bargay, Lotfi Benboubker, Laura Rosinol, Stefano Tarantolo, Howard Terebelo, Shiyi Yang, Jianping Wang, Ivo Nnane, Ming Qi, Michele Kosh, Maria Delioukina, Hartmut Goldschmidt
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Laura Rosinol, Albert Oriol, Rafael Rios, Maria Jesus Blanchard, Isidro Jarque, Joan Bargay, Miguel Teodoro Hernandez, Valentin Cabanas, Estrella Carrillo-Cruz, Anna Sureda, Joaquin Martinez-Lopez, Isabel Krsnik, Maria Esther Gonzalez, Luis Felipe Casado, Josep Maria Marti, Cristina Encinas, Felipe de Arriba, Luis Palomera, Antonia Sampol, Yolanda Gonzalez-Montes, Elena Cabezudo, Bruno Paiva, Noemi Puig, Maria Teresa Cedena, Javier de la Cruz, Maria-Victoria Mateos, Jesus San Miguel, Juan Jose Lahuerta, Joan Blade
Summary: This study compared the efficacy of maintenance therapy with RD and IRD in patients with multiple myeloma. The results showed that RD maintenance therapy was effective and discontinuation of maintenance therapy in patients with negative MRD at 2 years was safe.
Article
Oncology
J. L. van Dam, E. M. M. Verkolf, E. N. Dekker, B. A. Bonsing, S. O. Bratlie, L. A. A. Brosens, O. R. Busch, L. M. J. W. van Driel, C. H. J. van Eijck, S. Feshtali, P. Ghorbani, D. J. A. de Groot, J. W. B. de Groot, B. C. M. Haberkorn, I. H. de Hingh, B. van der Holt, T. M. Karsten, M. B. van der Kolk, K. J. Labori, M. S. L. Liem, O. J. L. Loosveld, I. Q. Molenaar, M. B. Polee, H. C. van Santvoort, J. de Vos Geelen, M. L. Wumkes, G. van Tienhoven, M. Y. V. Homs, M. G. Besselink, J. W. Wilmink, B. Groot Koerkamp, Dutch Pancreatic Cancer Grp
Summary: This study aims to compare the effectiveness of adjuvant chemotherapy after surgery and neoadjuvant chemotherapy followed by surgery. The objective is to find the optimal approach for the treatment of resectable pancreatic cancer.
Editorial Material
Hematology
Robert K. Hills
Summary: The paper by Noor et al. presents significant findings on the incidence and outcomes of patients with acute myeloid leukaemia in Afghanistan. It highlights the lower age of patients compared to the Western standard, reflecting the unique demographics of the country. These findings serve as an important initial step in identifying areas for improvement.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Niels W. C. J. van de Donk, Monique C. Minnema, Bronno van der Holt, Fredrik Schjesvold, Ka Lung Wu, Annemiek Broijl, Wilfried W. H. Roeloffzen, Alain Gadisseur, Giuseppe Pietrantuono, Ludek Pour, Vincent H. J. van der Velden, Thomas Lund, Massimo Offidani, Mariella Grasso, Luisa Giaccone, Wida Razawy, Paola Tacchetti, Katia Mancuso, Trine Silkjaer, Jo Caers, Sonja Zweegman, Roman Hajek, Reuben Benjamin, Annette Juul Vangsted, Mario Boccadoro, Francesca Gay, Pieter Sonneveld, Pellegrino Musto
Summary: The EMN12/HOVON-129 study aimed to improve the prognosis of patients with primary plasma cell leukemia by incorporating carfilzomib and lenalidomide in their treatment. The results showed a significant improvement in progression-free survival compared to previously published data. However, the prognosis of primary plasma cell leukemia remains inferior to that of multiple myeloma.
Article
Immunology
Aniko Sijs-Szabo, Avinash G. Dinmohamed, Jurjen Versluis, Bronno van der Holt, Mar Bellido, Mette D. Hazenberg, Michel van Gelder, Nicolaas P. M. Schaap, Ellen Meijer, Lotte E. van der Wagen, Constantijn J. M. Halkes, Anita W. Rijneveld, Jan J. Cornelissen
Summary: In this retrospective study, RIC-alloHSCT was compared with MAC-alloHSCT in older adult patients with acute lymphoblastic leukemia. The results showed that RIC-alloHSCT had lower nonrelapse mortality but a significantly higher relapse rate compared to MAC-alloHSCT. These findings suggest that MAC-alloHSCT may be a more effective consolidation therapy for reducing relapse.
Article
Medicine, General & Internal
Pablo R. Kappen, M. Mos, Johannes Jeekel, Clemens M. F. Dirven, Steven A. Kushner, Robert-Jan Osse, Michiel Coesmans, Marten J. Poley, Mathijs S. van Schie, Bronno van der Holt, M. Klimek, Arnaud J. P. E. Vincent
Summary: A prospective randomized controlled trial found that playing preferred music before, during, and after neurosurgery can reduce the risk of delirium after craniotomy, but this effect was not significant when using the DSM-5 diagnostic criteria. Music also increased heart rate variability. The validation of delirium screening tools and evaluation of long-term implications after craniotomy are needed.
Letter
Hematology
Kazimierz Groen, Fredrik H. Schjesvold, Bronno Van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen Van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. Van de Donk, Pieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman
Article
Oncology
Elias K. Mai, Thomas Hielscher, Uta Bertsch, Hans J. Salwender, Sonja Zweegman, Marc S. Raab, Markus Munder, Lucia Pantani, Katia Mancuso, Peter Brossart, Meral Beksac, Igor W. Blau, Jan Duerig, Britta Besemer, Roland Fenk, Peter Reimer, Bronno van der Holt, Mathias Haenel, Ivana von Metzler, Ullrich Graeven, Carsten Mueller-Tidow, Mario Boccadoro, Christof Scheid, Meletios A. Dimopoulos, Jens Hillengass, Katja C. Weisel, Michele Cavo, Pieter Sonneveld, Hartmut Goldschmidt
Summary: This study examines the incidence and causes of morbidity and mortality during induction therapy for newly diagnosed multiple myeloma (NDMM). It develops and validates a predictive risk score to identify NDMM patients at risk of severe infections or death. The study identifies four major risk factors and stratifies patients into low, intermediate, and high-risk groups. The risk score is validated in multiple trials incorporating quadruplet induction therapies.
Article
Hematology
Mhairi Copland, Cono Ariti, Ian F. Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahid Islam, Lars Kjeldsen, Alan K. Burnett, Robert K. Hills, Nigel Russell, Mike Dennis
Summary: Improving outcomes for older patients with acute myeloid leukaemia is still an unmet need. In this study, we evaluated the effectiveness of lenalidomide in combination with low-dose cytosine arabinoside compared to low-dose cytosine arabinoside alone in unfit patients aged over 60. The combination therapy showed a higher overall response rate, but there was no difference in overall survival between the two arms.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
